Gritstone bio, Inc.
GRTSDelisted Mar 5, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001656634
Gritstone bio, Inc. was delisted on Mar 5, 2025; its insiders filed their last Form 4 on Apr 8, 2025; 56 institutions reported holding it in 13F filings for Q3 2024, worth $20.7M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:52 PM ET
Revenue flow, FY2023
Where the revenue went in FY2023, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2023: $138.5M (847.3% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 12, 2024 | Jan 9, 2023 | Jan 10, 2022 | – | – |
| Revenue | $16.3M | $19.9M | $48.2M | $4.04M | $4.37M |
| Operating expenses | $156.0M | $140.4M | $123.4M | $110.1M | $102.3M |
| Research and development | $127.2M | $111.4M | $97.5M | $88.6M | $82.9M |
| Selling, general and administrative | $28.8M | $29.0M | $25.9M | $21.4M | $19.4M |
| Operating income | -$139.6M | -$120.4M | -$75.2M | -$106.0M | -$97.9M |
| Interest expense | $4.04M | $1.24M | – | – | – |
| Net income | -$138.5M | -$119.7M | -$75.1M | -$105.3M | -$94.4M |
| EPS, basic | $-1.20 | $-1.32 | – | – | – |
| EPS, diluted | $-1.20 | $-1.32 | – | – | – |
| Weighted shares, basic | 115.5M | 90.9M | – | – | – |
| Weighted shares, diluted | 115.5M | 90.9M | – | – | – |
| Margins and growth | |||||
| Operating margin | -854.3% | -603.8% | -156.0% | -2626.1% | -2243.8% |
| Net margin | -847.3% | -600.1% | -155.7% | -2608.7% | -2163.4% |
| Revenue growth, year over year | −18.1% | −58.6% | +1,094.3% | −7.5% | +267.7% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 12, 2024 | Jan 9, 2023 | Jan 10, 2022 | – | – |
| Cash and equivalents | $63.0M | $55.5M | $93.3M | $170.1M | $57.4M |
| Short-term investments | $16.3M | $116.4M | $108.3M | $1.00M | $70.4M |
| Total current assets | $87.4M | $182.9M | $220.6M | $175.4M | $131.3M |
| Property, plant and equipment | $17.3M | $21.3M | $21.6M | $22.1M | $26.9M |
| Total assets | $177.8M | $240.8M | $278.1M | $221.6M | $184.4M |
| Accounts payable | $3.82M | $8.69M | $4.23M | $9.58M | $4.62M |
| Total current liabilities | $27.3M | $34.8M | $40.0M | $27.0M | $19.5M |
| Long-term debt | $40.1M | $19.3M | – | – | – |
| Total liabilities | $125.9M | $70.0M | $62.0M | $54.8M | $50.0M |
| Shareholders' equity | $51.9M | $170.8M | $216.1M | $166.7M | $134.3M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 12, 2024 | Jan 9, 2023 | Jan 10, 2022 | – | – |
| Operating cash flow | -$121.6M | -$115.9M | -$50.7M | -$89.1M | -$85.0M |
| Capital expenditures | $4.57M | $5.87M | $5.46M | $3.52M | $16.2M |
| Free cash flow | -$126.2M | -$121.8M | -$56.1M | -$92.6M | -$101.2M |
| Depreciation and amortization | $7.59M | $6.56M | $6.35M | $6.64M | $4.75M |
| Stock-based compensation | $11.6M | $12.6M | $10.6M | $7.11M | $5.30M |
| Investing cash flow | $102.3M | -$13.0M | -$118.6M | $65.9M | $15.8M |
| Financing cash flow | $25.1M | $83.1M | $108.8M | $135.8M | $74.4M |
| Net change in cash | $5.81M | -$45.8M | -$60.5M | $112.6M | $5.22M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 71.1% | 63.0% | 21.9% | 176.1% | 121.4% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 8, 2024 | 118.1M | +26.9% | SEC |
| May 6, 2024 | 108.6M | +22.1% | SEC |
| Mar 1, 2024 | 98.1M | +11.9% | SEC |
| Nov 6, 2023 | 95.3M | +14.4% | SEC |
| Aug 7, 2023 | 93.1M | +27.5% | SEC |
| May 8, 2023 | 88.9M | +22.1% | SEC |
| Mar 7, 2023 | 87.7M | +20.6% | SEC |
| Nov 1, 2022 | 83.4M | +22.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.